_2020091018165303jzv.jpg "Decoding The World Of ETF")
-
My Account
Partnered by:
Associate Partners:
My Account
Partnered by:
Associate Partners:
Partnered by:
Associate Partners:
BSE Live
Jan 25, 16:00Prev. Close
3723.05
Open Price
3724.70
Bid Price (Qty.)
3570.00 (10)
Offer Price (Qty.)
3589.80 (3)
NSE Live
Jan 25, 16:04Prev. Close
3724.70
Open Price
3724.70
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
3591.80 (216)
| Half Yearly Results of AstraZeneca Pharma (in Rs. Cr.) | Sep '20 | Mar '20 | Sep '19 | Mar '19 | Sep '18 | |
| Net Sales/Income from operations | 403.05 | 418.76 | 413.04 | 405.50 | 322.80 | |
| Other Operating Income | -- | -- | -- | -- | -- | |
| Total Income From Operations | 403.05 | 418.76 | 413.04 | 405.50 | 322.80 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 44.83 | 38.17 | 32.04 | 39.08 | 26.34 | |
| Purchase of Traded Goods | 116.41 | 163.97 | 110.26 | 122.48 | 47.36 | |
| Increase/Decrease in Stocks | -11.12 | -41.11 | 1.90 | -33.77 | 32.38 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 111.99 | 133.80 | 102.90 | 112.52 | 88.02 | |
| Depreciation | 9.18 | 9.32 | 9.27 | 7.69 | 7.22 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | 20.73 | 24.76 | 31.00 | 39.50 | 40.30 | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 55.89 | 47.61 | 65.84 | 78.44 | 64.35 | |
| P/L Before Other | 55.14 | 42.24 | 59.85 | 39.56 | 16.82 | |
| Other Income | 7.36 | 6.84 | 6.15 | 9.51 | 6.78 | |
| P/L Before Int. | 62.51 | 49.07 | 66.00 | 49.07 | 23.60 | |
| Interest | 0.55 | 0.54 | 0.58 | -- | -- | |
| P/L Before Exceptional Items & Tax | 61.95 | 48.54 | 65.43 | 49.07 | 23.60 | |
| Exceptional Items | -- | -- | -- | -- | -- | |
| P/L Before Tax | 61.95 | 48.54 | 65.43 | 49.07 | 23.60 | |
| Tax | 16.98 | 12.25 | 29.49 | 10.15 | 8.07 | |
| P/L After Tax from Ordinary Activities | 44.97 | 36.28 | 35.93 | 38.92 | 15.53 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 44.97 | 36.28 | 35.93 | 38.92 | 15.53 | |
| Equity Share Capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 17.99 | 14.51 | 14.37 | -- | 6.21 | |
| Diluted EPS | 17.99 | -- | 14.37 | -- | 6.21 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 17.99 | 14.51 | 14.37 | -- | 6.21 | |
| Diluted EPS. | 17.99 | -- | 14.37 | -- | 6.21 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
21.12.2020
21.12.2020
07.12.2020
AstraZeneca Pharma share price gains after SII applies for emergency use of Covishield
06.11.2020
AstraZeneca Standalone September 2020 Net Sales at Rs 209.48 crore, up 0.48% Y-o-Y
06.11.2020
AstraZeneca Standalone September 2020 Net Sales at Rs 209.48 crore, up 0.48% Y-o-Y
05.11.2020
AstraZeneca Pharma India Q2 net profit up 83% at Rs 26 crore
11.08.2020
AstraZeneca Standalone June 2020 Net Sales at Rs 193.58 crore, down 5.37% Y-o-Y
10.08.2020
AstraZeneca Pharma India Q1 net profit declines 13% at Rs 18.63 crore
